Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6495541 | CLOVIS ONCOLOGY INC | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
Nov, 2023
(7 months from now) | |
US8754072 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
US9045487 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7531530 | CLOVIS ONCOLOGY INC | Therapeutic compounds |
Jul, 2024
(1 year, 3 months from now) | |
US7351701 | CLOVIS ONCOLOGY INC | Therapeutic compounds |
Jul, 2024
(1 year, 3 months from now) | |
US8071579 | CLOVIS ONCOLOGY INC | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(4 years from now) | |
US8143241 | CLOVIS ONCOLOGY INC | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(4 years from now) | |
US9861638 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
US10278974 | CLOVIS ONCOLOGY INC | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(7 years from now) | |
US8859562 | CLOVIS ONCOLOGY INC | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(8 years from now) | |
US9987285 | CLOVIS ONCOLOGY INC | High dosage strength tablets of rucaparib |
Aug, 2035
(12 years from now) | |
US10130636 | CLOVIS ONCOLOGY INC | High dosage strength tablets of rucaparib |
Aug, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 6, 2025 |
New Indication (I) | May 15, 2023 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating epithelial ovarian, fallopian tube, or primary peritoneal cancer, wherein the cancer is associated with a deleterious brca mutation; A method for treating ovarian cancer by admin...
Dosage: TABLET;ORAL
39
United States
19
Japan
10
United Kingdom
10
China
9
European Union
8
Australia
7
Denmark
7
Portugal
7
Spain
7
Korea, Republic of
7
Poland
7
Canada
6
Hong Kong
6
Russia
6
Norway
6
Brazil
5
Mexico
5
New Zealand
4
Israel
4
South Africa
4
Austria
4
Lithuania
4
Slovenia
4
Hungary
4
Singapore
3
Croatia
3
Cyprus
3
Taiwan, Province of China
2
Germany
2
Argentina
2
Luxembourg
2
RS
1
IB
1
Morocco
1
Colombia
1
Netherlands
1
San Marino
1
Iceland
1
Ecuador
1
Ukraine
1
EA
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic